Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 22 Apr 2024 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024 | 16 Apr 2024 |
| Transactions in Connection with Share Buy-back Program Genmab | 15 Apr 2024 |
| Transactions in Connection with Share Buy-back Program | 8 Apr 2024 |
| Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio | 3 Apr 2024 |